Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Healthy volunteers needed to set normal blood cell ranges for new analyzer

NCT ID NCT07031882

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study aims to establish normal reference ranges for white blood cells and granulocytes using a new device called the Liberty Analyzer WBC System. About 300 healthy adults aged 21 and older will provide blood samples. The results will help doctors interpret future test results from this device.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Non-diseased adults.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥21 years old at the time of study entry * Able to provide written informed consent Exclusion Criteria: * Inadequate use and understanding of the English language, requiring a translator * Undergone tattooing or body piercing within the 7 days prior to the study visit * Undergone vaccination within the 7 days prior to the study visit * Episode of upper respiratory infection within the 30 days prior to the study visit * Use of oral corticosteroid medications within the 30 days prior to the study visit * Undergone surgery within the 90 days prior to the study visit * Been hospitalised within the 90 days prior to the study visit * Donated blood or plasma within the 90 days prior to the study visit * Pregnant at the time of the study visit * Breastfeeding at the time of the study visit * Current diagnosis of anemia (including iron deficiency anemia, vitamin deficiency anemia, aplastic anemia and/or hemolytic anemia) * Current diagnosis of high blood pressure * Current diagnosis of diabetes mellitus * History or current diagnosis of chronic kidney disease or end-stage renal disease * History or current diagnosis of cancer * History or current diagnosis of cardiovascular disease * History or current use of radiotherapy of the chest or abdomen * History or current diagnosis of the following conditions known to affect the CBC differential count: * Immune Thrombocytopenic Purpura (ITP) * Systemic Lupus Erythematosus (SLE) * Rheumatoid Arthritis (RA) * Antiphospholipid Syndrome (APS) * Sjogren's Syndrome * Tuberculosis (TB) * HIV * Hepatitis B/C * G6PD Deficiency * Sickle Cell Disease/Trait * Inflammatory Bowel Disease (IBD) * Eptein Barr virus * CMV Cytomegalovirus * Myelodysplastic Syndromes (MDS) / CMML * Asplenia Participants who meet the following criteria will be excluded a posteriori: * Hemoglobin, hematocrit, red cell and/or total white blood cell count obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site. * Iron, ferritin, transferrin, total Iron Binding Capacity (TIBC) and/or transferrin saturation results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site. * Alanine aminotransferase (ALT), aspartate aminotransferase ( AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, conjugated bilirubin, albumin and/or total protein results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site. * Creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), sodium, potassium, chloride and/or bicarbonate results obtained by standard laboratory analysis of the participant's venous blood sample, that fall(s) outside of the applicable reference interval(s) in use at the study site. * C-reactive protein (CRP) results obtained by standard laboratory analysis of the participant's venous blood sample, that fall outside of the applicable reference interval in use at the study site. * Self-report to be taking medication(s) that are subsequently identified as interfering substances for the Liberty Analyzer WBC System

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Exercise & Sport Nutrition Laboratory

    College Station, Texas, 77843, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.